- Home
- DSM vs NMRA Comparison
DSM vs NMRA Comparison
Compare DSM & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- NMRA
- Stock Information
- Founded
- DSM 1989
- NMRA 2019
- Country
- DSM United States
- NMRA United States
- Employees
- DSM N/A
- NMRA N/A
- Industry
- DSM Investment Managers
- NMRA
- Sector
- DSM Finance
- NMRA
- Exchange
- DSM Nasdaq
- NMRA Nasdaq
- Market Cap
- DSM 275.8M
- NMRA 121.0M
- IPO Year
- DSM N/A
- NMRA 2023
- Fundamental
- Price
- DSM $5.70
- NMRA $0.84
- Analyst Decision
- DSM
- NMRA Buy
- Analyst Count
- DSM 0
- NMRA 8
- Target Price
- DSM N/A
- NMRA $9.29
- AVG Volume (30 Days)
- DSM 161.7K
- NMRA 1.4M
- Earning Date
- DSM 01-01-0001
- NMRA 08-05-2025
- Dividend Yield
- DSM 3.97%
- NMRA N/A
- EPS Growth
- DSM N/A
- NMRA N/A
- EPS
- DSM N/A
- NMRA N/A
- Revenue
- DSM N/A
- NMRA N/A
- Revenue This Year
- DSM N/A
- NMRA N/A
- Revenue Next Year
- DSM N/A
- NMRA N/A
- P/E Ratio
- DSM N/A
- NMRA N/A
- Revenue Growth
- DSM N/A
- NMRA N/A
- 52 Week Low
- DSM $4.69
- NMRA $0.61
- 52 Week High
- DSM $6.05
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- DSM 58.34
- NMRA 50.68
- Support Level
- DSM $5.55
- NMRA $0.72
- Resistance Level
- DSM $5.69
- NMRA $0.84
- Average True Range (ATR)
- DSM 0.04
- NMRA 0.07
- MACD
- DSM 0.02
- NMRA -0.01
- Stochastic Oscillator
- DSM 88.24
- NMRA 52.94
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.